Press release
Research Focused on the Bacterial Vaginosis Treatment Market Forecast up to 2025
Bacterial vaginosis occurs when conditions in the vagina change, disturbing the normal balance of bacteria in the vagina. Bacterial vaginosis may be asymptomatic; however, it is more commonly associated with vulvovaginal symptoms such as itching, discharge, odor, and discomfort. According to the Centers for Disease Control and Prevention (CDC), around 84% of women suffering from bacterial vaginosis have no symptoms. It is the most common disorder of genital tract among women of reproductive age and the prevalent cause of vaginal discharge and malodor.Bacterial vaginosis may lead to a number of gynecologic and obstetric complications such as preterm premature rupture of membranes (preterm PROM), preterm delivery and labor, spontaneous abortion, postpartum endometritis, postsurgical infections, post-caesarean-delivery wound infections, and subclinical pelvic inflammatory disease.
Obtain Report Details @ https://www.transparencymarketresearch.com/antimicrobial-susceptibility-testing-market.html
The exact cause of bacterial vaginosis is not known; however, the condition is reported more in women who have increased or new sexual activities. The disease is also associated with the use of vaginal deodorants, soaps, douches, bath oils, or bath additives that can alter the normal bacterial balance of the vagina. Bacterial vaginosis can be easily diagnosed by conducting a vaginal swab test. The treatment for bacterial vaginosis includes usage of antibiotics as well as vaginal gels and creams, which change the acidity of the vagina. Recurrence of bacterial vaginosis is common. It can be treated by changing the treatment course.
The global market for bacterial vaginosis treatment has been segmented based on treatment, distribution channel, and region. Based on treatment, the bacterial vaginosis treatment market can be segmented into antibiotics, vaginal creams & gels, and others. In terms of distribution channel, the market has been segmented into hospital pharmacies, online pharmacies, and independent pharmacies. Based on region, the global bacterial vaginosis treatment market can be segregated into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
Asia Pacific is expected to account for a significant share of the global market, in terms of revenue, during the forecast period. High percentage of people belonging to sexually active age group in countries such as India and China is likely to increase the demand of vaginal drugs in Asia Pacific in the near future. According to Index Mundi, a data portal that gathers facts and statistics; more than 16 crore women in China belonged to the age group of 15–24 years, while more than 10 crore women belonged to the age group of 25–54 years as of July 2016.
Download Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=31508
Index Mundi statistics also revealed that more than 10 crore women in India belonged to the age group of 15–25 years and more than eight crore women belonged to the age group of 25–54 years. Presence of such a large base of sexually active women that are susceptible to bacterial vaginosis is projected to augment the market for bacterial vaginosis treatment in Asia during the forecast period.
North America and Europe are expected to be lucrative markets for bacterial vaginosis treatment during the forecast period. High awareness among women about bacterial vaginosis and its treatment, rising prevalence of the disorder, and high disposable income are some of the factors driving the market in these regions. According to the data published by CDC, currently the prevalence of bacterial vaginosis in the U.S. is estimated to be 21.2 million (29.2%) in women aged 14–49 years.
Other regions such as Middle East & Africa and Latin America are expected to be prospective markets for bacterial vaginosis treatment in the near future, due to high prevalence of bacterial vaginosis, rising awareness about the disease and its treatment among women, rising disposable income, and highly developing health care industry in these regions.
Major players operating in the bacterial vaginosis treatment market are Allergan, AstraZeneca, Bliss GVS Pharma Ltd., Duchesnay Inc., Incepta Pharmaceuticals Limited., Pfizer Inc., Symbiomix Therapeutics, Starpharma Holdings, TOLMAR Pharmaceuticals Inc. and Teva Pharmaceutical Industries Ltd.
Pre-Book Full Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=31508<ype=S
About Us
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Contact Us
Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Research Focused on the Bacterial Vaginosis Treatment Market Forecast up to 2025 here
News-ID: 929919 • Views: …
More Releases from Transparency Market Research
Hypodermic Needles Market to Reach US$ 7.9 Billion by 2036 on Rising Injectable …
The global hypodermic needles market was valued at approximately US$ 4.2 billion in 2025 and is projected to reach around US$ 7.9 billion by 2036, expanding at a CAGR of nearly 5.8% from 2026 to 2036, driven by the rising prevalence of diabetes, cancer, and chronic diseases, growing demand for injectable drugs and biologics, and the expansion of global vaccination and immunization programs; increasing adoption of safety-engineered and disposable needles,…
Connected Car Market to Reach US$ 467.2 Billion by 2036, Driven by Rising Adopti …
The global connected car market is entering a high-growth phase as vehicles increasingly evolve into software-defined, data-driven mobility platforms. Valued at US$ 100.8 billion in 2025, the market is projected to reach an impressive US$ 467.2 billion by 2036, expanding at a robust CAGR of 12.3% from 2026 to 2036. This growth is fueled by rapid advancements in automotive connectivity, rising consumer demand for intelligent features, and strong integration of…
Density Gradient Media Market to Reach US$ 4.1 Billion by 2036, Driven by Rapid …
The global density gradient media market was valued at US$ 1.4 Billion in 2025 and is projected to reach US$ 4.1 Billion by 2036, expanding at a robust CAGR of 10.2% from 2025 to 2036. The market's rapid growth is primarily driven by increasing demand for rapid infectious disease screening, expanding cell therapy and immunology research, and continuous technological advancements improving sensitivity and multiplexing in laboratory workflows.
Access key findings and…
Functional Coffee Market Expanding at 7.6% CAGR Through 2035 - By Product Type / …
The global functional coffee market was valued at US$ 21.5 Bn in 2024 and is projected to reach US$ 48.1 Bn by 2035, expanding at a compound annual growth rate (CAGR) of 7.6% from 2025 to 2035. This steady growth trajectory reflects the strong convergence of coffee consumption habits with rising demand for functional and wellness-oriented beverages. Functional coffee has transitioned from a niche category to a mainstream product offering,…
More Releases for Bacterial
Prominent Bacterial Conjunctivitis Market Trend for 2025: Innovative Eye Drops T …
What Are the Projected Growth and Market Size Trends for the Bacterial Conjunctivitis Market?
The bacterial conjunctivitis market has grown steadily, projected to expand from $4.52 billion in 2024 to $4.76 billion in 2025, at a CAGR of 5.3%. Growth factors include rising bacterial infection cases, improved diagnostics, patient education programs, stringent regulatory frameworks, and physician training.
The bacterial conjunctivitis market is projected to grow steadily, reaching $5.54 billion by 2029 at…
Community-Acquired Bacterial Pneumonia Market
DelveInsight's "Community-Acquired Bacterial Pneumonia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Community-Acquired Bacterial Pneumonia, historical and forecasted epidemiology as well as the Community-Acquired Bacterial Pneumonia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Community-Acquired Bacterial Pneumonia market report provides current treatment practices, emerging drugs, Community-Acquired Bacterial Pneumonia market share of the individual therapies, and current…
Bacterial Conjunctivitis Drugs Market Report 2018: Segmentation by Disease Type …
Global Bacterial Conjunctivitis Drugs market research report provides company profile for Pfizer Inc., Novartis AG, F. Hoffmann-La Roche, Bayer Healthcare, Valeant Pharmaceutical International Inc., Perrigo Company Plc, Akorn Inc., Santen Pharmaceutical Co. Ltd., Allergan Plc. and Others.
This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth…
Bacterial Conjunctivitis Drugs Market: Rising Incidence of Ophthalmic Bacterial …
The U.S. market for bacterial conjunctivitis drugs has been declining sharply over the last few years. Analysts project the trend to continue in the coming years. In 2013, the market’s opportunity was valued at US$473.3 mn, which is likely to reduce to US$439.8 mn by 2024. In the coming years, the market will have to experience a patent cliff as the top U.S. brands of bacterial conjunctivitis drugs, such as…
Bacterial Conjunctivitis Drugs Market Driven by Rising Incidence of Ophthalmic B …
The U.S. market for bacterial conjunctivitis drugs is extremely fragmented, leading to commensurate competition among players. The entry barriers faced by new players despite having good research and development capabilities, is lack of capital, Transparency Market Research (TMR) states in its new report on the U.S. market for bacterial conjunctivitis drugs. R&D involves huge costs and this limits the production. Mergers and acquisitions and other forms of strategic alliances can…
Bacterial Conjunctivitis Drugs Market Driven by Rising Incidence of Ophthalmic B …
The U.S. market for bacterial conjunctivitis drugs has been declining sharply over the last few years. Analysts project the trend to continue in the coming years. In 2013, the market’s opportunity was valued at US$473.3 mn, which is likely to reduce to US$439.8 mn by 2024. In the coming years, the market will have to experience a patent cliff as the top U.S. brands of bacterial conjunctivitis drugs, such as…
